company background image
EXAI logo

Exscientia NasdaqGM:EXAI Stock Report

Last Price

US$4.84

Market Cap

US$633.5m

7D

3.2%

1Y

-21.9%

Updated

22 Nov, 2024

Data

Company Financials +

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

EXAI Stock Overview

An artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. More details

EXAI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Exscientia plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Exscientia
Historical stock prices
Current Share PriceUS$4.84
52 Week HighUS$7.91
52 Week LowUS$3.80
Beta0.84
1 Month Change-0.62%
3 Month Change-19.33%
1 Year Change-21.94%
3 Year Change-75.60%
5 Year Changen/a
Change since IPO-82.14%

Recent News & Updates

Recent updates

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Aug 08

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Jul 17
Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Exscientia: Too Much Pessimism

Jun 10

Exscientia: Drug Discovery Platform Attracting Partners And Cash

May 22

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Feb 26

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Jan 11
Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 12
Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Aug 31
New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Aug 25
We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Jul 21
Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Apr 22
Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Dec 30
We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Aug 31
The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Exscientia: Using AI To Power Drug Development

Aug 15

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

May 29
Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

Shareholder Returns

EXAIUS BiotechsUS Market
7D3.2%-1.0%-0.3%
1Y-21.9%-2.1%20.2%

Return vs Industry: EXAI underperformed the US Biotechs industry which returned 15.2% over the past year.

Return vs Market: EXAI underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is EXAI's price volatile compared to industry and market?
EXAI volatility
EXAI Average Weekly Movement8.5%
Biotechs Industry Average Movement11.4%
Market Average Movement6.0%
10% most volatile stocks in US Market18.4%
10% least volatile stocks in US Market3.0%

Stable Share Price: EXAI has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: EXAI's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012483Dave Hallettwww.exscientia.ai

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.

Exscientia plc Fundamentals Summary

How do Exscientia's earnings and revenue compare to its market cap?
EXAI fundamental statistics
Market capUS$633.50m
Earnings (TTM)-US$188.33m
Revenue (TTM)US$21.36m

29.7x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EXAI income statement (TTM)
RevenueUK£17.07m
Cost of RevenueUK£28.63m
Gross Profit-UK£11.56m
Other ExpensesUK£138.95m
Earnings-UK£150.51m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.15
Gross Margin-67.74%
Net Profit Margin-881.79%
Debt/Equity Ratio0.1%

How did EXAI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/22 11:16
End of Day Share Price 2024/11/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exscientia plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Chris ShibutaniGoldman Sachs
Brendan SmithTD Cowen